We were delighted to talk with Dr Kristin Kaasen Jørgensen (Akershus University Hospital, Nordbyhagen, Norway) around the NOR-DRUM B study, investigating proactive therapeutic drug monitoring during maintenance therapy with infliximab.
The abstract entitled ‘Proactive Therapeutic Drug Monitoring is superior to standard treatment during maintenance therapy with infliximab; results from a 52-week multicentre randomised trial of 450 patients; the NOR-DRUM B study’(Presentation no. OP09) was presented at the 17th Congress of ECCO, February 16-19, 2022!
- What are the current limitations of biologic drugs in IBD? (0:19)
- What are the potential benefits and pitfalls of a proactive therapeutic drug monitoring as opposed to a reactive strategy? (1:08)
- What were the aims and design of the NOR-DRUM B study? (2:49)
- What were the study endpoints and how well were these achieved? (4:24)
- What will be the impact of these findings on clinical practice? (5:36)
Disclosures: Kristin Kaasen Jørgensen has received personal fees from Roche, BMS, and Norgine.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual 2022.
Share this Video
Related Videos In Gastroenterology
Jayne Doherty, UEG Week 2022: Response to COVID-19 vaccination in patients with inflammatory bowel disease taking TNF antagonists
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19. The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN […]
Gil Melmed: Research highlights in inflammatory bowel disease from 2022
In 2022, 3 therapies were approved for the treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. including a JAK inhibitor, and s1P receptor modulator in UC and an IL-23 inhibitor in Crohn’s disease. Advances in research in combination therapy and personalised medicine were also at the forefront in 2022. It was a […]
Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis
touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications. Questions Could you give us a brief overview of the health burden of Crohn’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!